Abstract

BackgroundTransplantation of pancreatic β cells generated in vitro from pluripotent stem cells (hPSCs) such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed as an alternative therapy for diabetes. Though many differentiation protocols have been developed for this purpose, lentivirus-mediated forced expression of transcription factors (TF)—PDX1 and NKX6.1—has been at the forefront for its relatively fast and straightforward approach. However, considering that such cells will be used for therapeutic purposes in the future, it is desirable to develop a procedure that does not leave any footprint on the genome, as any changes of DNAs could potentially be a source of unintended, concerning effects such as tumorigenicity. In this study, we attempted to establish a novel protocol for rapid and footprint-free hESC differentiation into a pancreatic endocrine lineage by using synthetic mRNAs (synRNAs) encoding PDX1 and NKX6.1. We also tested whether siPOU5F1, which reduces the expression of pluripotency gene POU5F1 (also known as OCT4), can enhance differentiation as reported previously for mesoderm and endoderm lineages.MethodssynRNA-PDX1 and synRNA-NKX6.1 were synthesized in vitro and were transfected five times to hESCs with a lipofection reagent in a modified differentiation culture condition. siPOU5F1 was included only in the first transfection. Subsequently, cells were seeded onto a low attachment plate and aggregated by an orbital shaker. At day 13, the degree of differentiation was assessed by quantitative RT-PCR (qRT-PCR) and immunohistochemistry for endocrine hormones such as insulin, glucagon, and somatostatin.ResultsBoth PDX1 and NKX6.1 expression were detected in cells co-transfected with synRNA-PDX1 and synRNA-NKX6.1 at day 3. Expression levels of insulin in the transfected cells at day 13 were 450 times and 14 times higher by qRT-PCR compared to the levels at day 0 and in cells cultured without synRNA transfection, respectively. Immunohistochemically, pancreatic endocrine hormones were not detected in cells cultured without synRNA transfection but were highly expressed in cells transfected with synRNA-PDX1, synRNA-NKX6.1, and siPOU5F1 at as early as day 13.ConclusionsIn this study, we report a novel protocol for rapid and footprint-free differentiation of hESCs to endocrine cells.

Highlights

  • Transplantation of pancreatic β cells generated in vitro from pluripotent stem cells such as embryonic stem cells (ESCs) or induced pluripotent stem cells has been proposed as an alternative therapy for diabetes

  • Generation of PDX1+/NKX6.1+ pancreatic endoderm/ endocrine precursor cells As a first step to establish a differentiation protocol, we started with the protocol reported by Russ et al [3], because their method is simple and rapid compared with other protocols for the differentiation of hPSCs into insulin-producing cells

  • We analyzed the expression levels of PDX1 and NKX6.1 by quantitative RT-PCR (qRT-PCR) after five transfections and compared the results with those of day 0 (D 0) that is a cellular state of undifferentiated ES cells and cells treated with differentiation medium alone

Read more

Summary

Introduction

Transplantation of pancreatic β cells generated in vitro from pluripotent stem cells (hPSCs) such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed as an alternative therapy for diabetes. The application of this therapy is limited because of the shortage of donor islets and the requirement of lifelong immunosuppression therapy after transplantation To overcome these obstacles, the use of pancreatic β cells differentiated in vitro from human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed [1,2,3,4,5,6,7]. The use of pancreatic β cells differentiated in vitro from human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed [1,2,3,4,5,6,7] These differentiation protocols require a rather long period of time and complicated culture steps, posing further challenges for their clinical application

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.